About Anna Suk-Fong

Dr. Lok graduated from University of Hong Kong Medical School. She completed her medicine training at Queen Mary Hospital and hepatology training in London under Dame Sheila Sherlock.  She was a faculty at the University of Hong Kong until she moved to the United States in 1992. Dr. Lok joined the University of Michigan in 1995 as Director of the Hepatology Program. She became Associate Chair for Clinical Research in the Department of Internal Medicine in 2008 and Assistant Dean for Clinical Research in 2016. 
Dr. Lok’s research focuses on natural history and treatment of hepatitis B and C. She has published more than 450 papers on viral hepatitis and liver diseases including four iterations of the American Association for the Study of Liver Diseases (AASLD) guidelines on “Hepatitis B”. She also participated in the development of the first World Health Organization guidelines on hepatitis B and C. Dr. Lok has made important contributions to the understanding of factors influencing the progression of hepatitis B and C, and the development of new treatments of these diseases. She was one of the top 1% most cited researchers in the world for the period 2002-2012. Dr. Lok has mentored more than 50 fellows and junior faculty worldwide, many are now professors and heads of their departments. 
Dr. Lok received many awards throughout her career including the Distinguished Scientist Award from the Hepatitis B Foundation and the Distinguished Women Scientist Award from the American Gastroenterological Association (AGA) in 2008, the Distinguished Service Award from the AASLD in 2011, the Distinguished Scientific Achievement Award from the American Liver Foundation in 2015, the William Beaumont Prize in Gastroenterology from the AGA in 2016, a Gold Medal Award from the Canadian Association for the Study of the Liver and an Hon DSc from the University of Hong Kong in 2017.
Dr. Lok served as Associate Editor of HEPATOLOGY in 2002-6, co-Editor of Journal of Viral Hepatitis in 2007-9 and a Senior Associate Editor of GASTROENTEROLOGY in 2011-2012. 
Dr. Lok is currently President of the AASLD.

This speaker will be presenting at the following session(s)

  • Strategic direction 1: strategic information for focused action

    Golden Hall

    Day: 1 November

    Time: 13:30

    The Summit’s agenda takes the Global Health Sector Strategy on Viral Hepatitis (GHSS) - and its 5 strategic directions - as its framework. In this plenary session, strategic direction 1 looks at advocacy, political commitment and national planning.

    Chairs: Dr. Leolin Katsidzira, University of Zimbabwe College of Health Sciences and Tatjana Reic, European Liver Patients’ Association


    • Global viral hepatitis situation and response.

      Dr. Marc Bulterys, World Health Organization

    • WHO country profiles report.

      Prof. Sharon Hutchinson, Glasgow Caledonian University, UK

    • The power of people: integrating civil society in the global hepatitis response.

      Charles Gore, World Hepatitis Alliance

    • The role of liver societies in the global viral hepatitis response.

      Anna Lok, American Association for the Study of Liver Diseases

    • Country level experience of using strategic information to inform their national hepatitis response. 
      Zimbabwe - Rapid assessments: Dr. Leolin Katsidzira, University of Zimbabwe College of Health Sciences
      Vietnam - Hepatitis surveillance: Dr. Tran Dai Quang, Ministry of Health, Viet Nam
    • Q&A session.

    Session objectives:

    To highlight

    • The role and importance of strategic information in planning and monitoring national responses.

    • The priority actions for countries and role of WHO in supporting countries.

    • The latest data on the global viral hepatitis situation and response.

    • Progress made in integrating civil society in the global viral hepatitis response and on global awareness activities.

    • Country examples demonstrating the important role of strategic information for focused action.

  • Liver societies' role towards viral hepatitis elimination


    Day: 2 November

    Time: 08:00

    Topics to be discussed:

    • Prevention of mother to child transmission of HBV and strategies to increase HBV vaccine coverage (in particular birth dose coverage) and antiviral therapy for highly viremic HBsAg+ mothers.
    • Improving diagnosis of persons chronically infected with HBV or HCV.
    • Improving linkage to care of persons diagnosed to have chronic HBV or HCV, in particular vulnerable populations and persons living in rural areas.
    • Improving access to antiviral treatment of persons with chronic HBV or HCV.